Author Verified
Published: Dec 2013
ACE Report #5931
Ace Report Cover Metabolic Disorders

Prostate cancer: Zoledronic acid as an adjuvant therapy is well-tolerated and improves BMD

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):382-6. doi: 10.1038/pcan.2013.35. Epub 2013 Oct 1

Contributing Authors: LA Kachnic SL Pugh P Tai M Smith E Gore AB Shah AG Martin HE Kim A Nabid CA Lawton

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.